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Urachal carcinoma is a rare and aggressive form of bladder cancer involving the urachus, a
fibrous remnant of the allantois that extends from the bladder to the umbilicus. We report
this case of a 49-year-old women with primary urachal adenocarcinoma treated with
partial cystectomy who relapsed 5 years after surgery with lung metastases. This patient
with unremarkable medical history presented with abdominal discomfort and a palpable
pelvic mass. Follow-up imaging reveals a large mass on the dome of the bladder extending
from the urachus. Subsequent ultrasound-guided biopsy result was suggestive of an ura-
chal mucinous adenocarcinoma. The patient was treated surgically with a partial
cystectomy.
© 2016 Published by Elsevier Inc. on behalf of under copyright license from the University of
Washington. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Case report
A 49-year-old female patient with unexceptional past medical
history presented to her primary care physician with com-
plaints of a 12-month history of abdominal pain and an
enlarging mass sensation along her previous cesarean section
scar. On physical examination, a large anterior pelvic mass
was palpable, firm, and nontender in the midline of supra-
pubic region slightly to the left. Other than increased
frequency and nocturia, she did not complain of urgency,
incontinence, pain with voiding, or hematuria.
Imaging of the abdomen was ordered to further assess the
mass. Initial ultrasound (US) examination revealed a 15-cm
mass localized to the dome of the urinary bladder (Figs. 1A
and B). Subsequent magnetic resonance imaging (MRI) scan
confirmed amassmeasuring 14 8.5 7.3 cm arising from the
left lower rectus abdominis muscle (Figs. 2-4). It extendslared that no competing
).
on behalf of under copyr
se (http://creativecommoanteriorly into the subcutaneous tissue and posteriorly
imparts significant mass effect on the dome of the bladder.
Contrast-enhanced computed tomography (CT) scan of the
abdomen also confirms an enhancing mass lesion on the wall
of the urinary bladder (Fig. 5). Given the imaging findings, the
differential diagnosis at the time included: soft tissue
sarcoma, dermatofibrosarcoma protuberans, and desmoid
tumor. The patient underwent a cystoscopy, which detected
the presence of a submucosal bulge at the urinary bladder
dome in the expected area of the residual urachus, consistent
with large urachal adenocarcinoma. An US-guided biopsy of
the cystic mass showed significant histologic findings indic-
ative of low grademucinous adenocarcinoma. Colonoscopy at
the time did not reveal evidence of primary cancer involving
the colon. Also, CT scan of chest, abdomen, and pelvis in
addition to positron emission tomography (PET) scan did not
reveal regional nor distant metastasis at the time.interests exist.
ight license from the University of Washington. This is an open
ns.org/licenses/by-nc-nd/4.0/).
Fig. 1 e (A) Transabdominal ultrasound scan of the pelvis
shows heterogeneous mass measuring 4.7 cm by 9 cm
inseparable from the urinary bladder. (B) Transabdominal
ultrasound scan of the pelvis showing heterogenous mass
with internal vascular flow arrows.
Fig. 2 e T2W axial magnetic resonance (MR) image through
the pelvis showing multiseptated hyperintense mass
exerting mass effect on the anterior lateral surface of the
urinary bladder.
R a d i o l o g y C a s e R e p o r t s x x x ( 2 0 1 6 ) 1e52The tumor was removed surgically. The patient underwent
a partial cystectomy, hysterectomy, bilateral salpingo-
oophorectomy, ureterolysis, and left iliac node biopsy.
Pathology confirmed the diagnosis of urachal adenocarci-
noma with negative margins. No adjuvant chemotherapy
treatment took place. After surgery, the patient is assessed by
CT scan of chest, abdomen, and pelvis performed every 6
months (Fig. 6). Five years after her surgery, follow-up chest
CT scan revealed multiple pulmonary metastasis.Discussion
The urachus is a vestigial musculofibrous band of tissue
located in the space of Retzius surrounded anteriorly by the
transversalis fascia and posteriorly by the peritoneum [1].
During early embryonic development, the urachal canal con-
nects the allantois to the early fetal bladder [2]. Following the
descend of the bladder into the pelvis during the 4thmonth of
fetal development, it is stretched until it becomes the median
umbilical ligament that joins the umbilicus to the dome of the
bladder. Although the tubular structure diminishes with
advancing age, it persists in a small proportion of adults [3].
Urachal cancer was originally described by Hue and
Jacquin in 1963. As a rare and devastating malignancy of thebladder, it accounts for an estimated 0.01% of all adult can-
cers, 0.5%-2.0% of all bladder malignancies, and 20%-40% of
primary bladder adenocarcinomas [1,4e6]. The mean survival
for a locally advanced or metastatic disease is between 12 and
24 months, and the 5-year survival rate is only 43% [7e9]. Late
symptom presentation, propensity for early local invasion,
and distal metastasis are 3 characteristics of urachal cancer
that lead to its poor prognosis [9].
Because early urachal cancer is not accompanied with
symptoms, patients often present at the time of diagnosis
with higher stage and poor prognosis [7]. Only when invasion
of the bladder takes place, patients would present with com-
mon symptoms such as irritative voiding, mucous-like
discharge, and hematuria [10]. The strongest predictors of
urachal malignancy are hematuria and age greater than 55
years [9]. As the predominant presenting symptom, hematu-
ria occurs in 90% of patients and increases the risk of malig-
nancy by 17-fold [7,9,11,12]. Abdominal symptoms such as
umbilical pain and discharge have also been reported.
On rare occasions, urachal adenocarcinoma can metasta-
size to the ovaries. These metastases are similar to primary
mucinous ovarian adenocarcinomas both macroscopically
and microscopically [13]. Mucin stains are positive in 69% of
urachal adenocarcinoma [4]. To differentiate primary ovarian
tumors from secondary, immunohistochemistry panel con-
sisting of CK7, CK20, CDX2, MUC2, 34bE12, and b-catenin can
be used. Although this panel of biochemical markers can
differentiate primary vs secondary ovarian tumors, it can also
help in defining the secondary tumor [13].
Diagnosis of urachal cancers has been made easier by the
MD Anderson Cancer Center (MDACC) criteria consisting of
Fig. 3 e T1 FS postcontrast axial MRI image through the
pelvis showing enhancing septations within the mass
lesion anterior lateral to the urinary bladder.
Fig. 5 e Axial image, contrast-enhanced CT scan of the
abdomen and/or pelvis in the portal venous phase
demonstrates heterogeneously enhancing mass lesion
adjacent to the anterior lateral wall of the urinary bladder
with associated left external iliac lymph node. There is a
loss of fat plane with associated soft tissue stranding,
highly suspicious for invasion into anterior abdominalwall.
R a d i o l o g y C a s e R e p o r t s x x x ( 2 0 1 6 ) 1e5 32 main criteria and 4 supportive criteria [11]. The 2 main
criteria consist of: midline location of the tumor and a sharp
demarcation between the tumor and normal surface epithe-
lium [10]. Supportive criteria include: an enteric histology; the
absence of urothelial dysplasia; the absence of cystitis cystica;
and the absence of a primary adenocarcinoma of anotherFig. 4 e T1 FS postcontrast axial MRI image through the
pelvis showing loss of tissue plane between the mass and
urinary bladder suggesting bladder origin and/or invasion
(arrows).origin [8,10]. However, urothelial surface involvement and
presence of cystitis cystica are not grounds for excluding
urachal carcinomas from differential diagnosis [14].Fig. 6 e Contrast-enhanced CT scan of the abdomen and
pelvis in the portal venous phase 4 years after surgical
removal of the tumor. No evidence of local recurrence.
Incisional hernia.
Table 1 e The urachal cancer staging system as defined
by Sheldon et al in 1984.
Stage Definition
Stage I Urachal cancer confined to urachal mucosa
Stage II Urachal cancer with invasion confined to
urachus itself
Stage IIIA Local urachal cancer extension to bladder
Stage IIIB Local urachal cancer extension to abdominal
wall
Stage IIIC Local urachal cancer extension to peritoneum
Stage IIID Local urachal cancer extension to viscera
other than bladder
Stage IVA Metastatic urachal cancer to lymph nodes
Stage IVB Metastatic urachal cancer to distant sites
R a d i o l o g y C a s e R e p o r t s x x x ( 2 0 1 6 ) 1e54Nonetheless, accurate diagnosis of urachal carcinoma is
facilitated by a high degree of clinical suspicion and imaging
correlation.
Standard imaging workup for urachal cancer includes US,
CT scan, and/or MRI evaluation of the abdomen and pelvis.
US is often the initial imaging modality. On US, the tumor is
observed as a soft tissue mass, which may consist of
heterogeneity and calcification. While nonspecific, internal
vascularity can sometimes be seen with Doppler imaging. CT
scan and MRI, on the other hand, are often used for local
staging and evaluation of distant metastasis. On CT scan, in
84% of cases, the tumor is mixed solid and cystic [15],
whereas in the reminder of the cases, the tumor appears
solid. The cystic component commonly seen in these tumors
is mucin. As a sensitive modality for detecting calcifications,
peripheral calcification is also commonly seen in the CT
scan. Regarding positioning, the bulk of the tumor can be
seen outside the lumen of the bladder in 88% of the cases.
To distinguish it from urothelial cancer, bladder wall inva-
sion is seen in 92% of adenocarcinomas, and distant
metastasis is found in 48% of the cases. On MRI, sagittal
images are important to define the location of the tumor.
Focal areas of high intensity on T2 sequence are produced by
mucinous component, and are highly suggestive of adeno-
carcinoma. The solid component is isointense to soft tissue
on T1 and enhances postcontrast administration. In addi-
tion, cystoscopy is also recommended. Diagnosis of urachal
carcinoma is usually confirmed by cystoscopy and biopsy [9].
Immunohistochemistry may assist in the distinction
between primary and secondary adenocarcinomas. Namely,
primary adenocarcinomas of the bladder will be positive for
both CK7 and CK20, whereas colonic adenocarcinomas
express only CK20 [12].
One of the most significant predictors of urachal cancer
prognosis is surgicalmargin status [16]. Hence, proper surgical
intervention has proven critical to the survival of patients [9].
The gold standard surgical approach for the management of
localized urachal cancer is an excision of the urachus, umbi-
licus, and partial cystectomy combined with bilateral pelvic
lymphadenectomy [16]. While radical cystectomy has tradi-
tionally been done, partial cystectomy with en block
urachectomy up to the umbilicus cures 70% of patients.Further resection of the urachal ligament and umbilicus is
recommended to ensure negative margins as 7% of urachal
cancer can occur at the umbilicus [4,9,17].
Tumor stage at presentation has been important in pre-
dicting outcome after surgery [16]. Three different staging
systems of urachal cancer have been proposed, although
they are yet to be validated: Sheldon, Mayo, and Ontario
staging systems. Sheldon et al [4] Proposed a staging system
involving localization of the tumor (Table 1). It classifies
early stage urachal cancer as localized in the urachal mu-
cosa, whereas late stage cancer involves the extraurachal
structures: pT1dno invasion beyond the urachal mucosa;
pT2dinvasion confined to the urachus; pT3dlocal extension
to the (A) bladder, (B) abdominal wall, and (C) viscera other
than the bladder, and pT4dmetastasis to (A) regional lymph
nodes and (B) distant sites. A more simplified system has
been proposed by Ashley et al [9]. The Ontario staging sys-
tem is yet another simplified classification of urachal tumor
involving 4 stages: confined to urachus (T1), confined to
bladder (T2), Invading surrounding fat (T3), and extending to
the peritoneum (T4) [5].
Currently, there are no standard protocol for the treatment
of urachal adenocarcinomawith adjuvant chemotherapy. The
role of chemotherapy and radiation therapy and its benefit to
patient is yet unclear [7].r e f e r e n c e s
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